In Reply We thank Deutch for his thoughtful response to our study,1 in which we reported that the glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces body weight, improves glucose tolerance, and decreases systolic blood pressure in patients with schizophrenia receiving clozapine or olanzapine. Deutch correctly pointed out that GLP-1 receptor stimulation can dampen activation of the reward pathways (eg, reduction of cocaine-induced dopamine elevation2) and therefore suggested that a detailed assessment of liraglutide-induced psychiatric symptoms, particularly the so-called negative symptoms, such as anhedonia and blunted affect, should be performed before GLP-1 receptor agonists are used to counter antipsychotic-induced body weight gain and metabolic disturbances.
Fink-Jensen A, Correll CU, Vilsbøll T. Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply. JAMA Psychiatry. 2017;74(11):1173–1174. doi:10.1001/jamapsychiatry.2017.2702
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: